← Oncology Approval Tracker

FDA DECISION ·

Rolvedon

eflapegrastim-xnst · Spectrum Pharmaceuticals

FDA approvalNew therapyChemotherapy-associated febrile neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Reduction of infection manifested by febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive cancer regimens associated with a clinically significant febrile-neutropenia risk.

LAMPGEN ANALYSIS

Why it matters

This adds a long-acting granulocyte colony-stimulating factor option for preventive supportive care.

What research teams should watch

Confirm regimen risk and synchronize administration with the chemotherapy cycle.

PRIMARY RECORDS

Sources